RxDoctor Payments Data

Nicholas Gelormini, MD

Psychiatry · Johnston, RINPI 1992970248

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 51.0% of the total.

$597in general payments, 2019–2025

Across 25 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$304
  • Neurocrine Biosciences, Inc.$69
  • Otsuka America Pharmaceutical, Inc.$61
  • Indivior Inc.$36
  • E.r. Squibb & Sons, L.L.C.$30
  • Vanda Pharmaceuticals Inc.$29
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$597 in reported general payments places this provider in the 75th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$19,785
Medicare patients
31
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate48$121,470
VraylarCariprazine Hcl58$77,066
Abilify MaintenaAripiprazole22$65,064
BelsomraSuvorexant55$25,286
AuvelityDextromethorphan Hbr/Bupropion14$14,507
Clozapine139$10,932
Aripiprazole139$8,556
QelbreeViloxazine Hcl13$8,171
VyvanseLisdexamfetamine Dimesylate21$8,115
Chlorpromazine Hcl29$6,458
DayvigoLemborexant20$6,221
TrintellixVortioxetine Hydrobromide12$5,313
Gabapentin197$4,934
Paliperidone ErPaliperidone19$4,214
Prazosin Hcl162$3,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$304$77,06658 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$61$65,06422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 209 psychiatry providers in Rhode Island.

Other psychiatry in Johnston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →